Adiponectin mediated metabolic and sphingolipid alterations in preventing endothelial dysfunction.

Area of Science:

• Cardiovascular Biology
• Metabolic Research
• Cellular Signaling

Background:

• Endothelial dysfunction is an early sign of atherosclerosis.
• Adiponectin, an adipose hormone, has insulin-sensitizing and anti-inflammatory effects, protecting against atherosclerosis.
• Understanding adiponectin's mechanisms in endothelial cells is crucial for cardiovascular health.

Purpose of the Study:

• To investigate metabolic and sphingolipid alterations in endothelial cells related to adiponectin's protective effects.
• To elucidate the role of sphingosine kinases in adiponectin-mediated protection and mitochondrial function.
• To identify potential therapeutic targets for endothelial dysfunction.

Main Methods:

• Human Umbilical Endothelial Cells (HUVECs) were treated with Tumor Necrosis Factor-alpha (TNF-α) to induce dysfunction.
• AdipoRon (adiponectin agonist) and SKI-I (sphingosine kinase inhibitor) were used.
• Metabolic profiling, sphingolipid analysis, and RNA sequencing were performed.

Main Results:

• TNF-α upregulated glycolysis and downregulated fatty acid oxidation and mitochondrial ATP production; AdipoRon partially reversed these effects.
• TNF-α altered intracellular and extracellular sphingolipid levels (ceramides, S1P); AdipoRon reversed these changes.
• AdipoRon counteracted TNF-α's transcriptional alterations, while sphingosine kinase inhibition induced mitochondrial dysfunction.

Conclusions:

• Adiponectin partially restores endothelial cell metabolism and reverses sphingolipid alterations induced by TNF-α.
• Sphingosine kinases play a novel role in modulating mitochondrial function in endothelial cells.
• Targeting endothelial metabolism and sphingolipid pathways may offer therapeutic strategies for endothelial dysfunction and atherosclerosis.